Micropulse transscleral diode laser cyclophotocoagulation in the treatment of refractory glaucoma

Background: Transscleral diode laser cyclophotocoagulation (TSCPC) is an established method of treatment for refractory glaucoma, but is associated with significant complications. This study evaluates the efficacy and safety of a new form of TSCPC using micropulse diode laser and trans-pars plana treatment with a novel contact probe. Methods: Prospective interventional case series of 40 eyes of 38 consecutive patients with refractory glaucoma treated with micropulse TSCPC with a novel probe. Outcomes measured were success, hypotony and response rates. Results: The mean age of patients was 63.2 +/- 16.0 years. The mean follow-up period was 16.3 +/- 4.5 months. The mean intraocular pressure (IOP) before micropulse TSCPC was 39.3 +/- 12.6 mmHg. Mean IOP decreased to 31.1 +/- 13.4 mmHg at 1 day, 28.0 +/- 12.0 mmHg at 1 week, 27.4 +/- 12.7 mmHg at 1 month, 27.1 +/- 13.6 mmHg at 3 months, 25.8 +/- 14.5 mmHg at 6 months, 26.6 +/- 14.7 mmHg at 12 months and 26.2 +/- 14.3 mmHg at 18 months (P < 0.001 at all time points). No patient had hypotony or loss of best-corrected visual acuity. The overall success rate after a mean of 1.3 treatment sessions was 72.7%. Conclusion: Micropulse TSCPC is a safe and effective method of lowering IOP in cases of refractory glaucoma and is comparable with conventional TSCPC.